These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 34970555)
21. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. Tsuchiya A; Takeuchi S; Iwasawa T; Kumagai M; Sato T; Motegi S; Ishii Y; Koseki Y; Tomiyoshi K; Natsui K; Takeda N; Yoshida Y; Yamazaki F; Kojima Y; Watanabe Y; Kimura N; Tominaga K; Kamimura H; Takamura M; Terai S Inflamm Regen; 2020; 40():14. PubMed ID: 32582401 [TBL] [Abstract][Full Text] [Related]
22. Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential. Xiong J; Bao L; Qi H; Feng Z; Shi Y Curr Stem Cell Res Ther; 2021; 16(2):105-108. PubMed ID: 32479246 [TBL] [Abstract][Full Text] [Related]
23. Mesenchymal Stem Cells (MSCs) as a Potential Therapeutic Strategy in COVID-19 Patients: Literature Research. Coelho A; Alvites RD; Branquinho MV; Guerreiro SG; Maurício AC Front Cell Dev Biol; 2020; 8():602647. PubMed ID: 33330498 [TBL] [Abstract][Full Text] [Related]
24. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19. Yen BL; Yen ML; Wang LT; Liu KJ; Sytwu HK Stem Cells Transl Med; 2020 Oct; 9(10):1163-1173. PubMed ID: 32526079 [TBL] [Abstract][Full Text] [Related]
25. Can mesenchymal stem cells be used to treat COVID-19-induced pneumonia? (Review). Çetin İ; Topçul M Biomed Rep; 2020 Dec; 13(6):62. PubMed ID: 33194191 [TBL] [Abstract][Full Text] [Related]
26. Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19-Associated Cytokine Storm. Langmuir P; Yeleswaram S; Smith P; Knorr B; Squier P Dela J Public Health; 2020 Jul; 6(2):50-54. PubMed ID: 34467111 [TBL] [Abstract][Full Text] [Related]
27. Logistics of an advanced therapy medicinal product during COVID-19 pandemic in Italy: successful delivery of mesenchymal stromal cells in dry ice. Astori G; Bernardi M; Bozza A; Catanzaro D; Chieregato K; Merlo A; Santimaria M; Barbazza R; Amodeo G; Ciccocioppo R; Elice F; Ruggeri M J Transl Med; 2020 Nov; 18(1):451. PubMed ID: 33256746 [TBL] [Abstract][Full Text] [Related]
28. COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not. Akkoc T Adv Exp Med Biol; 2020; 1298():167-176. PubMed ID: 32648245 [TBL] [Abstract][Full Text] [Related]
29. Multipotent Mesenchymal Stromal Cells in Rheumatoid Arthritis and Systemic Lupus Erythematosus; From a Leading Role in Pathogenesis to Potential Therapeutic Saviors? El-Jawhari JJ; El-Sherbiny Y; McGonagle D; Jones E Front Immunol; 2021; 12():643170. PubMed ID: 33732263 [TBL] [Abstract][Full Text] [Related]
30. Mesenchymal stem cell research progress for the treatment of COVID-19. Yao D; Ye H; Huo Z; Wu L; Wei S J Int Med Res; 2020 Sep; 48(9):300060520955063. PubMed ID: 32972277 [TBL] [Abstract][Full Text] [Related]
31. Microencapsulated Wharton Jelly-derived adult mesenchymal stem cells as a potential new therapeutic tool for patients with COVID-19 disease: an in vitro study. Montanucci P; Pescara T; Greco A; Francisci D; Basta G; Calafiore R Am J Stem Cells; 2021; 10(3):36-52. PubMed ID: 34552816 [TBL] [Abstract][Full Text] [Related]
32. Mesenchymal Stem Cells as a Treatment Strategy for Coronavirus Disease 2019 (COVID-19): Need for Authority Regulations and Clinical Guidelines. Tufan AC Curr Stem Cell Res Ther; 2021; 16(4):465-480. PubMed ID: 33238848 [TBL] [Abstract][Full Text] [Related]
33. Editorial: Current Progress in Mesenchymal Stem/Stromal Cell Research. da Silva Meirelles L; Bieback K; Bolontrade MF Front Cell Dev Biol; 2021; 9():658903. PubMed ID: 33681232 [No Abstract] [Full Text] [Related]
34. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect. Can A; Coskun H Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878 [TBL] [Abstract][Full Text] [Related]
35. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review. Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187 [TBL] [Abstract][Full Text] [Related]
36. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report. Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053 [TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity. Wei J; Zhao J; Han M; Meng F; Zhou J J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811 [TBL] [Abstract][Full Text] [Related]
38. Can Stem Cells Beat COVID-19: Advancing Stem Cells and Extracellular Vesicles Toward Mainstream Medicine for Lung Injuries Associated With SARS-CoV-2 Infections. Chrzanowski W; Kim SY; McClements L Front Bioeng Biotechnol; 2020; 8():554. PubMed ID: 32574317 [TBL] [Abstract][Full Text] [Related]
39. Cytokine Storm Drugs Move from CAR T to COVID-19. Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479 [TBL] [Abstract][Full Text] [Related]
40. Editorial: A Compendium of Recent Research on Stem Cell-Based Therapy for Covid-19. Hmadcha A; Soria B; Zhao RC; Smani T; Valverde I Front Cell Dev Biol; 2021; 9():813384. PubMed ID: 34970555 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]